MicroRNA-210 and Endoplasmic Reticulum Chaperones in the Regulation of Chemoresistance in Glioblastoma

被引:33
|
作者
Lee, Derek [1 ]
Sun, Stella [1 ]
Zhang, Xiao Qin [1 ]
De Zhang, Ping [1 ]
Ho, Amy S. W. [1 ]
Kiang, Karrie M. Y. [1 ]
Fung, Ching Fai [1 ]
Lui, Wai Man [1 ]
Leung, Gilberto K. K. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Dept Surg, Pokfulam, Hong Kong, Peoples R China
来源
JOURNAL OF CANCER | 2015年 / 6卷 / 03期
关键词
Glioblastoma; miRNA; P4HB; ER stress reponse; chemoresistance; temozolomide; HYPOXIA; MIR-210; CANCER; CELLS; EPIDEMIOLOGY; TEMOZOLOMIDE; PROGNOSIS; GLIOMA;
D O I
10.7150/jca.10765
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma multiforme (GBM) is the commonest primary brain tumour in adults characterized by relentless recurrence due to resistance towards the standard chemotherapeutic agent temozolomide (TMZ). Prolyl 4-hydroxylase, beta polypeptide (P4HB), an endoplasmic reticulum (ER) chaperone, is known to be upregulated in TMZ-resistant GBM cells. MicroRNAs (miRNAs) are non-protein-coding transcripts that may play important roles in GBM chemoresistance. We surmised that miRNA dysregulations may contribute to P4HB upregulation, hence chemoresistance. We found that miRNA-210 (miR-210) was P4HB-targeting and was highly downregulated in TMZ-resistant GBM cells. Forced overexpression of miR-210 led to P4HB downregulation and a reduction in TMZ-resistance. A reciprocal relationship between their expressions was also verified in clinical glioma specimens. Our study is the first to demonstrate a potential link between miR-210 and ER chaperone in determining chemosensitivity in GBM. The findings have important translational implications in suggesting new directions of future studies.
引用
收藏
页码:227 / 232
页数:6
相关论文
共 50 条
  • [1] MicroRNA-210 regulates cell proliferation and apoptosis by targeting regulator of differentiation 1 in glioblastoma cells
    Zhang, Shuai
    Lai, Niansheng
    Liao, Keman
    Sun, Jun
    Lin, Yuchang
    FOLIA NEUROPATHOLOGICA, 2015, 53 (03) : 236 - 244
  • [2] Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma
    Cai, Haiqing
    Lin, Lijun
    Cai, Haikang
    Tang, Mingjie
    Wang, Zhigang
    MEDICAL ONCOLOGY, 2013, 30 (02)
  • [3] MicroRNA-210 overexpression predicts poorer prognosis in glioma patients
    Lai, Nian-sheng
    Dong, Qing-sheng
    Ding, Hao
    Miao, Zeng-li
    Lin, Yu-chang
    JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (05) : 755 - 760
  • [4] Downregulation of microRNA-210 inhibits osteosarcoma growth in vitro and in vivo
    Liu, Changjian
    Tang, Xin
    MOLECULAR MEDICINE REPORTS, 2015, 12 (03) : 3674 - 3680
  • [5] Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma
    Lai, N-s
    Wu, D-g
    Fang, X-g
    Lin, Y-c
    Chen, S-s
    Li, Z-b
    Xu, S-s
    BRITISH JOURNAL OF CANCER, 2015, 112 (07) : 1241 - 1246
  • [6] Prognostic role of microRNA-210 in various carcinomas: a meta-analysis
    Xie, Xuejiao
    Wu, Wenhong
    Liang, Ludong
    Han, Shuai
    Chen, Ting
    Pan, Shangling
    Xue, Meijuan
    Li, Shikang
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (09): : 15283 - 15289
  • [7] MicroRNA-210 and its theranostic potential
    Ren, Chun-Xia
    Leng, Rui-Xue
    Fan, Yin-Guang
    Pan, Hai-Feng
    Wu, Chang-Hao
    Ye, Dong-Qing
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (11) : 1325 - 1338
  • [8] MicroRNA-210 A unique and pleiotropic hypoxamir
    Chan, Stephen Y.
    Loscalzo, Joseph
    CELL CYCLE, 2010, 9 (06) : 1072 - 1083
  • [9] microRNA-210 is involved in the regulation of postmenopausal osteoporosis through promotion of VEGF expression and osteoblast differentiation
    Liu, Xiao-Dong
    Cai, Feng
    Liu, Liang
    Zhang, Yan
    Yang, An-Li
    BIOLOGICAL CHEMISTRY, 2015, 396 (04) : 339 - 347
  • [10] Prognostic evaluation of microRNA-210 in various carcinomas: Evidence from 19 studies
    Liu, Yincheng
    Wang, Yichun
    Xu, Qitong
    Zhou, Xiang
    Qin, Zhiqiang
    Chen, Chen
    Zhang, Qijie
    Tian, Ye
    Zhang, Chao
    Li, Xiao
    Qin, Chao
    MEDICINE, 2017, 96 (43)